The new kidney disease: Improving global outcomes (KDIGO) guidelines - Expert clinical focus on bone and vascular calcification

Clinical Nephrology

Volumn 74, Issue 6, 2010, Pages 423-432

  London, G ^a   Coyne, D ^b   Hruska, K ^c   Malluche, H H ^d   Martin, K J ^e  

^a Centre Hospitalier Manhes   (France)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Chronic kidney disease; Kidney disease: improving global outcomes; Mineral and bone disorder; Phosphorus; Renal bone disease

Indexed keywords

BUFFER; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

ARTICLE; BIOCHEMISTRY; BLOOD VESSEL CALCIFICATION; CALCIFICATION; HUMAN; HYPERPARATHYROIDISM; HYPERPHOSPHATASEMIA; KIDNEY CLEARANCE; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; RENAL OSTEODYSTROPHY; STAGING; VITAMIN BLOOD LEVEL;

BONE DISEASES, METABOLIC; CALCINOSIS; CALCIUM; CHRONIC DISEASE; EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY DISEASES; PARATHYROID HORMONE; PHOSPHORUS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; UNITED STATES; VASCULAR DISEASES; VITAMIN D;

EID: 78649861800     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.2379/CN106512     Document Type: Article

References (52)

1. CKD-MBD Work Group. Kidney disease: improving global outcomes (KDIGO). KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009; 76 (Suppl): 1-130.
2. Adragao T, Herberth J, Monier-Faugere MC, Branscum AJ, Ferreira A, Frazao JM, Dias Curto J, Malluche HH. Low bone volume - a risk factor for coronary calcifications in hemodialysis patients. Clin J Am Soc Nephrol. 2009; 4: 450-455.
3. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008; 74: 148-157.
4. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994; 46: 855-861.
5. London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008; 19: 1827-1835.
6. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004; 15: 1943-1951.
7. Rodriguez-Garcia M, Gomez-Alonso C, Naves-Diaz M, Diaz-Lopez JB, Diaz-Corte C, Cannata-Andia JB, on behalf of the Asturias Study Group. Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol Dial Transplant. 2009; 24: 239-249.
8. Rodriguez Garcia M, Naves Diaz M, Cannata Andia JB. Bone metabolism, vascular calcifications and mortality: associations beyond mere coincidence. J Nephrol. 2005; 18: 458-463.
9. Jara A, Chacon C, Burgos ME, Droguett A, Valdivieso A, Ortiz M, Troncoso P, Mezzano S. Expression of gremlin, a bone morphogenetic protein antagonist, is associated with vascular calcification in uraemia. Nephrol Dial Transplant. 2009; 24: 1121-1129.
10. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol. 2003; 23: 489-494.
11. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000; 36: 1115-1121.
12. Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ, Gokal R. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int. 1993; 44: 1071-1077.
13. Monier-Faugere MC, Malluche HH. Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant. 1996; 11 (Suppl): 111-120.
14. Salusky IB, Coburn JW, Brill J, Foley J, Slatopolsky E, Fine RN, Goodman WG. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int. 1988; 33: 975-982.
15. Asci G, Kircelli F, Sevinc E, Duman S, Ozkahya M, Toz H, Monier-Faugere MC, Malluche HH, Ok E. Bone markers for non-invasive diagnosis of adynamic bone disease in hemodialysis patients. J Am Soc Nephrol. 2008; 19: 4.
16. Ferreira A, Frazao JM, Monier-Faugere M-C, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH, on behalf of the Sevelamer Study Group. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008; 19: 405-412.
17. Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int. 1992; 38 (Suppl): 62-67.
18. Adragao T, Ferreira A, Frazao J, Gil C, Oliveira C, Sarmento J, Ribeiro S, Dickson J, Carvalho B, Rodrigues I, Baldaia J, Faugere M, Malluche H. Vascular calcifications and bone turnover in hemodialysis patients. Nephrol Dial Transplant. 2006; 21: 292.
19. Malluche HH, Monier-Faugere MC. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol. 1994; 4: 1631-1642.
20. Malluche HH, Monier-Faugere MC. Renal osteodystrophy: what's in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin Nephrol. 2006; 65: 235-242.
21. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006; 69: 1945-1953. (Pubitemid 43924257)
22. Herberth J, Monier-Faugere MC, Mawad HW, Branscum AJ, Herberth Z, Wang G, Cantor T, Malluche HH. The five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patients. Clin Nephrol. 2009; 72: 5-14.
23. Komaba H, Goto S, Fukagawa M. Critical issues of PTHassays in CKD.Bone. 2009; 44: 666-670.
24. Sawaya BP, Butros R, Naqvi S, Geng Z, Mawad H, Friedler R, Fanti P, Monier-Faugere MC, Malluche HH. Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease. Kidney Int. 2003; 64: 737-742.
25. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42: 1-201.
26. Bervoets AR, Spasovski GB, Behets GJ, Dams G, Polenakovic MH, Zafirovska K, Van Hoof VO, De Broe ME, D'Haese PC. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis. 2003; 41: 997-1007.
27. Fahrleitner-Pammer A, Herberth J, Browning SR, Obermayer-Pietsch B, Wirnsberger G, Holzer H, Dobnig H, Malluche HH. Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res. 2008; 23: 1850-1858.
28. Perco P, Wilflingseder J, Bernthaler A, Wiesinger M, Rudnicki M, Wimmer B, Mayer B, Oberbauer R. Biomarker candidates for cardiovascular disease and bone metabolism disorders in chronic kidney disease: a systems biology perspective. J Cell Mol Med. 2008; 12: 1177-1187.
29. Adragao T, Herberth J, Monier-Faugere MC, Branscum AJ, Ferreira A, Frazao JM, Malluche HH. Femoral bone mineral density reflects histologically determined cortical bone volume in hemodialysis patients. Osteoporos Int. 2009; 4: 619-625.
30. Mathew S, Tustison KS, Sugatani T, Chaudhary LR, Rifas L, Hruska KA. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol. 2008; 19: 1092-1105.
31. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. JAmSoc Nephrol. 2004; 15: 2208-2218.
32. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB, Sr, Gaziano JM, Vasan RS. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007; 167: 879-885.
33. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005; 16: 520-528.
34. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005; 112: 2627-2633.
35. Craver L, Marco MP, Martinez I, Rue M, Borras M, Martin ML, Sarro F, Valdivielso JM, Fernandez E. Mineral metabolism parameters throughout chronic kidney disease stages 1-5 achievement of K/DOQI target ranges. Nephrol Dial Transplant. 2007; 22: 1171-1176.
36. Martinez I, Saracho R, Montenegro J, Llach F. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant. 1996; 11 (Suppl): 22-28.
37. Gutiérrez O, Mannstadt M, Isakova T, Rauh-Hain J, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.NEngl J Med. 2008; 359: 584-592.
38. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001; 38: 938-942.
39. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000; 342: 1478-1483.
40. Merjanian R, Budoff M, Adler S, Berman N, Mehrotra R. Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney Int. 2003; 64: 263-271.
41. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000; 15: 1014-1021.
42. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005; 68: 1815-1824.
43. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005; 100: 8-19.
44. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. 2003; 85 (Suppl): 73-78.
45. Freemont AJ, Hoyland JA, Denton J. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol. 2005; 64: 428-437.
46. Malluche HH, Siami GA, Swanepoel C, Wang GH, Mawad H, Confer S, Smith M, Pratt RD, Monier- Faugere MC, on behalf of the SPD405-307 Lanthanum Carbonate Study Group. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol. 2008; 70: 284-295.
47. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-252.
48. QunibiW, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, Budoff M. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the calcium acetate renagel evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008; 51: 952-965.
49. Floege J. Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them? Nephrol Dial Transplant. 2008; 23: 3050-3052.
50. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007; 72: 1130-1137.
51. Wilson R, Zhang P, Pratt R. Retrospective outcomes analyses of a 2-year comparative study of lanthanum carbonate vs standard therapy. J Am Soc Nephrol. 2008; 19: 320.
52. Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2008; 69: 269-278.